PCH - Shifting the T1D Paradigm: Early Detection, Disease Modification, and Beta Cell Preservation - Michael Haller, MD, MS-CI (University of Florida) (Virtual Session)

At the end of this presentation, participants should be able to:

• Implement risk-based screening approaches to facilitate timely identification of presymptomatic type 1 diabetes (T1D)
• Analyze T1D screening results to determine disease stage and inform appropriate monitoring and referral decisions
• Develop individualized treatment strategies that incorporate disease-modifying therapies to delay T1D progression in eligible patients
• Recognize the importance of beta cell preservation on T1D prognosis and outcomes
• Review emerging approaches aimed at beta cell preservation and their potential future application in new-onset T1D

About the presenter(s):

Michael Haller, MD, MS-CI
Professor and Chief | Silverstein Family Eminent Scholar
Pediatric Endocrinology | University of Florida

Dr. Haller is Professor and Chief of Pediatric Endocrinology at the University of Florida where he coordinates an active research team focused on the prediction, prevention and reversal of type 1 diabetes. Dr. Haller is the Chair of the NIH funded Type 1 Diabetes TrialNet and serves as the PI of the University of Florida TrialNet Clinical Center. Dr. Haller has lead efforts to demonstrate the efficacy of low-dose thymoglobulin to preserve beta cell function in type 1 diabetes and is now leading an international study of a fully human antithymocyte globulin (SAB-142) in new onset T1D. Additionally, Dr. Haller served as the primary investigator for the pediatric inhaled insulin study (INHALE-1) and the CD40L Fabulinus study. Dr. Haller has published over 200 peer reviewed manuscripts and book chapters and currently sits in the Silverstein Family Eminent Scholar Chair in support of his work in pediatric type 1 diabetes.